We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dysregulation of Retinoic Acid Signaling in Stem Cells Spurs Tumor Growth

By LabMedica International staff writers
Posted on 05 Nov 2018
A team of cancer researchers identified the retinoic acid molecular signaling pathway as being a factor that helps to prevent the development of colorectal cancer.

Investigators at the Christiana Care Health System (Wilmington, DE, USA) were studying the factors controlling the differentiation of colon cancer stem cells (SCs) into undifferentiated tumor cells or, in some cases, into differentiated (non-cancerous) colon cells. More...
Since tumor development is driven by stem cell overpopulation, and in light of earlier findings that the enzyme aldehyde dehydrogenase (ALDH) was both a marker for SCs in many tissues and a key enzyme in retinoid acid (RA) signaling, the investigators examined RA signaling in normal and malignant colonic SCs.

The investigators analyzed normal and malignant colonic tissues and colorectal cancer (CRC) cell lines to see if retinoid receptors (RXR & RAR) were exclusively expressed in ALDH+ SCs, and if RA signaling changed during CRC development. Specifically, they determined whether RA signaling regulated cancer SC proliferation, differentiation, sphere formation, and population size.

Results published in the October 5, 2018, online edition of the journal Oncotarget revealed that RXR & RAR were expressed in ALDH+ colonic SCs, but not in normal cells. Western blotting/immunostaining of CRCs revealed that RA signaling components became overexpressed in parallel with ALDH overexpression, which coincided with the known overpopulation of ALDH+ SCs that occurs during, and drives, CRC development.

Treatment of SCs with all-trans retinoic acid (ATRA) was found to decrease proliferation, sphere formation, and ALDH+ SC population size and to induce differentiation. Thus, dysregulation of RA signaling in colonic SCs likely contributed to overpopulation of ALDH+ SCs and CRC growth.

“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” said senior author Dr. Bruce Boman, a senior research scientist at the Christiana Care Health System. “Our thinking has shifted to the insight that cancers originate in tissue stem cells through dysregulation or malfunction of the self-renewal process, and that cancer stem cells drive tumor growth. It follows that the optimal way to treat cancer (especially advanced cancer) is to eliminate cancer stem cells. We discovered that the retinoic acid or RA signaling pathway acts to induce differentiation of colon cancer stem cells and reduce cancer stem cell overpopulation, which puts the brakes on the primary mechanism that drives colon cancer development.”

Related Links:
Christiana Care Health System


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Biochemistry Analyzer
Chemi+ 8100
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.